Amicus Therapeutics Inc (NASDAQ: FOLD) has reported E.P.S. of $-0.02 for its third fiscal quarter (ending September 30) versus $-0.07 for the same period a year ago — a decline of -71%. For the latest four quarters through September 30, E.P.S. were $-0.34 compared to $-0.59 a year ago — a decline of -42%.
Recent Price Action
On 11/6/24, Amicus Therapeutics Inc (NASDAQ: FOLD) stock declined by -4.3%, closing at $11.24. Moreover, this decline was accompanied by exceptionally high trading volume at 268% of normal. Relative to the market the stock has been weak over the last nine months and has declined -2.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, FOLD is expected to continue to be a major Value Builder.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Amicus Therapeutics has a slightly negative Power Rating of 38 and a very low Appreciation Score of 11, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment